“The smaller number of patients in the trial would make approval tougher with a phase 2. It's possible but we might need a 50% or more improvement to get conditional approval. Which leronlimab might be capable of but the variability of patient condition with 60 patients could work for or against us.”

Does anybody know if patient criteria will screen for Delta32 deletions?